drug
as of 2026-07-01Bifeprunox
bifeprunox
MeSH C509981
at a glance
small molecule
Pre-approval / investigational in the US
Developed by Solvay Pharmaceuticals
14 trials in the graph
Synthesized from structured facts only — each point cited above.
Mechanism & identity
Modality
small molecule
Indications
Trials
14
Efficacy of Bifeprunox in Patients With Schizophrenia
NCT00658645Phase 3Terminated
Efficacy of Bifeprunox in Patients With Schizophrenia
NCT00704509Phase 3Terminated
Study Evaluating Bifeprunox in Patients With Schizophrenia.
NCT00366327Phase 3Terminated
Study Comparing Bifeprunox to Risperidone in Treatment of Outpatients With Schizophrenia With Weight as Primary Endpoint
NCT00366704Phase 3Terminated
Compare the Effects of Bifeprunox and Quetiapine on Weight Changes in Stable Schizophrenic Patients
NCT00396214Phase 3Terminated
Bifeprunox in the Treatment of Schizophrenia
NCT00193687Phase 3Completed
Treatment of Elderly Subjects With Psychosis and Behavioral Disturbances Associated With Dementia of the Alzheimer's Type
NCT00160147Phase 3Terminated
Bifeprunox Extension to Extension Study in Patients With Schizophrenia
NCT00861497Phase 3Terminated
Progressively Decreasing Titration Schedules of Bifeprunox in Subjects With Schizophrenia or Bipolar Disorder
NCT00139919Phase 2Completed
Bifeprunox in the Treatment of Schizophrenia
NCT00193713Phase 3Completed
To Evaluate the Impact of Treatment Interruption on Re-initiation of Bifeprunox
NCT00141479Phase 2Completed
Twice Daily Titration Study of Bifeprunox in Subjects With Schizophrenia
NCT00139906Phase 2Completed
Patient-reported Outcomes in the Treatment of Schizophrenia
NCT00230828Phase 3Completed
Open Label Extension Study of Bifeprunox
NCT00366171Phase 3Completed
KOLs & investigators
1
Facts & assertions
0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
company
trial
indication
indication
indication
indication
KOL
Global Clinical Director Solvay
personKOL score —